[Cost analysis for ambulatory treatment of cystic fibrosis patients in Germany. Overview of the prospective study results]
- PMID: 19618138
- DOI: 10.1007/s00063-009-1112-9
[Cost analysis for ambulatory treatment of cystic fibrosis patients in Germany. Overview of the prospective study results]
Abstract
Purpose: Main objective of this study is to assess and evaluate resource use in outpatient treatment of cystic fibrosis (CF) in Germany and to compare this with current reimbursement.
Methods: Outpatient treatment was evaluated in seven different CF centers.Clinical patient data, resource use, and time consumption were recorded in 2006. A micro-costing approach was used to price resource use data.
Results: Mean costs of 488 Euros per patient (n = 326) and quarter occurred. Remuneration (252 Euros per patient/quarter) covered only 52% of the total costs. Furthermore, a considerable time and financial burden for patients as well as decreasing quality of life with increasing age were found. Costs for medication came to 21,604 Euros per patient/year.
Conclusion: Human resources in German CF centers today already are below the requirements set by the European consensus for standards of CF care. It will be crucial in assuring a high level of patient care to reach a cost-covering reimbursement scheme in Germany.
Similar articles
-
Cost of illness of cystic fibrosis in Germany: results from a large cystic fibrosis centre.Pharmacoeconomics. 2012 Sep 1;30(9):763-77. doi: 10.2165/11588870-000000000-00000. Pharmacoeconomics. 2012. PMID: 22690685
-
Resource usage in outpatient care and reimbursement for cystic fibrosis in Germany.Pediatr Pulmonol. 2011 Mar;46(3):278-85. doi: 10.1002/ppul.21364. Epub 2010 Nov 17. Pediatr Pulmonol. 2011. PMID: 24081887
-
[Drug treatment of cystic fibrosis - cost patterns and savings potential for outpatient treatment].Med Klin (Munich). 2010 Dec;105(12):887-900. doi: 10.1007/s00063-010-1154-z. Epub 2011 Jan 16. Med Klin (Munich). 2010. PMID: 21240588 German.
-
[Healthcare expenditure].Bull Acad Natl Med. 2012 Oct;196(7):1443-9. Bull Acad Natl Med. 2012. PMID: 23815025 Review. French.
-
Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies.Pharmacoeconomics. 2003;21(14):1001-24. doi: 10.2165/00019053-200321140-00002. Pharmacoeconomics. 2003. PMID: 13129414 Review.
Cited by
-
Conceptualization and Implementation of the Central Information Portal on Rare Diseases: Protocol for a Qualitative Study.JMIR Res Protoc. 2018 May 11;7(5):e112. doi: 10.2196/resprot.7425. JMIR Res Protoc. 2018. PMID: 29752252 Free PMC article.
-
Cost of illness of cystic fibrosis in Germany: results from a large cystic fibrosis centre.Pharmacoeconomics. 2012 Sep 1;30(9):763-77. doi: 10.2165/11588870-000000000-00000. Pharmacoeconomics. 2012. PMID: 22690685
-
Rare is frequent and frequent is costly: rare diseases as a challenge for health care systems.Eur J Health Econ. 2015 Mar;16(2):113-8. doi: 10.1007/s10198-014-0639-8. Eur J Health Econ. 2015. PMID: 25355295 No abstract available.
-
Staff costs of hospital-based outpatient care of patients with cystic fibrosis.Health Econ Rev. 2011 Aug 3;1(1):10. doi: 10.1186/2191-1991-1-10. Health Econ Rev. 2011. PMID: 22828269 Free PMC article.
-
[Analysis of costs and profits of ambulatory care of Marfan patients after initiation of a novel German legal directive (116 b SGB V)].Med Klin (Munich). 2010 Aug;105(8):529-37. doi: 10.1007/s00063-010-1090-y. Epub 2010 Sep 8. Med Klin (Munich). 2010. PMID: 20824410 German.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical